Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
Florida Hospital Orlando
mi
from
Orlando, FL
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
Northwell Health NCORP
mi
from
Lake Success, NY
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
Northwell Health NCORP
mi
from
Lake Success, NY
Click here to add this to my saved trials
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
Union Hospital of Cecil County
mi
from
Elkton, MD
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
Northwell Health- Center for Advanced Medicine
mi
from
Lake Success, NY
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
Northwell Health- Center for Advanced Medicine
mi
from
Lake Success, NY
Click here to add this to my saved trials
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
North Shore University Hospital
mi
from
Manhasset, NY
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated:  12/31/1969
NYP Weill Cornell Medical Center
mi
from
New York, NY
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase II Study of the Addition of Azacitidine (NSC#102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML
Status: Enrolling
Updated: 12/31/1969
NYP Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated:  12/31/1969
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated: 12/31/1969
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated:  12/31/1969
Louisiana Center for Bleeding & Clotting Disorders
mi
from
New Orleans, LA
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated: 12/31/1969
Louisiana Center for Bleeding & Clotting Disorders
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill Hospital
mi
from
Chapel Hill, NC
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill Hospital
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated:  12/31/1969
The Pennsylvania State University and Milton s. Hershey Medical Center
mi
from
Hershey, PA
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated: 12/31/1969
The Pennsylvania State University and Milton s. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health - Warren G. Magnuson Clinical Center
mi
from
Bethesda, MD
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health - Warren G. Magnuson Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center, Hemostasis/Hemophilia Clinic
mi
from
Nashville, TN
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center, Hemostasis/Hemophilia Clinic
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated:  12/31/1969
Maisonneuve-Rosemont Hospital
mi
from
Montreal,
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Status: Enrolling
Updated: 12/31/1969
Maisonneuve-Rosemont Hospital
mi
from
Montreal,
Click here to add this to my saved trials
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Davis, CA
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Davis, CA
Click here to add this to my saved trials
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Syracuse, NY
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
An Open-label Phase 1 Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration in Two Cohorts of Previously Treated Male Subjects With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters
A Comparative Clinical Trial to Assess the Accuracy of the TensorTip, a Novel Non Invasive Device for the Measurement of Physiological and Blood Chemistry Parameters
Status: Enrolling
Updated:  12/31/1969
Atlantic Health - Morristown Memorial Hospital- Cardiovascular Medicine
mi
from
Morristown, NJ
A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters
A Comparative Clinical Trial to Assess the Accuracy of the TensorTip, a Novel Non Invasive Device for the Measurement of Physiological and Blood Chemistry Parameters
Status: Enrolling
Updated: 12/31/1969
Atlantic Health - Morristown Memorial Hospital- Cardiovascular Medicine
mi
from
Morristown, NJ
Click here to add this to my saved trials
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated:  12/31/1969
Stanford University Medical School
mi
from
Stanford, CA
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated: 12/31/1969
Stanford University Medical School
mi
from
Stanford, CA
Click here to add this to my saved trials
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated:  12/31/1969
Emory Children's Center
mi
from
Atlanta, GA
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated: 12/31/1969
Emory Children's Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated:  12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hosp / Baylor Univ
mi
from
Houston, TX
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hosp / Baylor Univ
mi
from
Houston, TX
Click here to add this to my saved trials
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center (CPMC) Research Institute
mi
from
San Francisco, CA
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center (CPMC) Research Institute
mi
from
San Francisco, CA
Click here to add this to my saved trials
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated:  12/31/1969
Hospices Civils de Lyon
mi
from
Lyon,
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
Status: Enrolling
Updated: 12/31/1969
Hospices Civils de Lyon
mi
from
Lyon,
Click here to add this to my saved trials
Safety and Efficacy Study for AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Open-Label Pilot Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 28-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and/or 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Augusta, GA
Safety and Efficacy Study for AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Open-Label Pilot Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 28-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and/or 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Safety and Efficacy Study for AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Open-Label Pilot Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 28-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and/or 4
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Safety and Efficacy Study for AKB-6548 in Subjects With Chronic Kidney Disease and Anemia
Phase 2a Open-Label Pilot Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 28-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and/or 4
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Iron Mediated Vascular Disease in Sickle Cell Anemia Patients
Iron-mediated Vascular Disease in Sickle Cell Disease.
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Iron Mediated Vascular Disease in Sickle Cell Anemia Patients
Iron-mediated Vascular Disease in Sickle Cell Disease.
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Phase I Study to Determine the Safety and Tolerability of Escalating Doses of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Status: Enrolling
Updated:  12/31/1969
Augusta University
mi
from
Augusta, GA
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Phase I Study to Determine the Safety and Tolerability of Escalating Doses of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Status: Enrolling
Updated: 12/31/1969
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Colorado and Colorado Fetal Care Center
mi
from
Aurora, CO
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Colorado and Colorado Fetal Care Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated:  12/31/1969
University of MD /Department of Obstetrics, Gynecology & Reproductive Sciences
mi
from
Baltimore, MD
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated: 12/31/1969
University of MD /Department of Obstetrics, Gynecology & Reproductive Sciences
mi
from
Baltimore, MD
Click here to add this to my saved trials
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated:  12/31/1969
Fetal Care Center of Cincinnati, Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated: 12/31/1969
Fetal Care Center of Cincinnati, Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated:  12/31/1969
The Ohio State University / OSU Fetal Therapy Program
mi
from
Columbus, OH
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated: 12/31/1969
The Ohio State University / OSU Fetal Therapy Program
mi
from
Columbus, OH
Click here to add this to my saved trials
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated:  12/31/1969
Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated: 12/31/1969
Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated:  12/31/1969
Fetal Treatment Program of New England, Hasbro Children's Hospital, The Warren Alpert Medical School of Brown University.
mi
from
Providence, RI
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated: 12/31/1969
Fetal Treatment Program of New England, Hasbro Children's Hospital, The Warren Alpert Medical School of Brown University.
mi
from
Providence, RI
Click here to add this to my saved trials
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated:  12/31/1969
The Texas Fetal Center, Children's Memorial Hermann Hospital, University of Texas Medical School
mi
from
Houston, TX
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated: 12/31/1969
The Texas Fetal Center, Children's Memorial Hermann Hospital, University of Texas Medical School
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated:  12/31/1969
Fetal Therapy Program, Evergrenn Hospital Medical Center
mi
from
Kirkland, WA
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated: 12/31/1969
Fetal Therapy Program, Evergrenn Hospital Medical Center
mi
from
Kirkland, WA
Click here to add this to my saved trials
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hospital, University of Toronto
mi
from
Toronto,
Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery
A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hospital, University of Toronto
mi
from
Toronto,
Click here to add this to my saved trials
Eltrombopag for Moderate Aplastic Anemia
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Eltrombopag for Moderate Aplastic Anemia
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Gene Therapy for Fanconi Anemia
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Gene Therapy for Fanconi Anemia
Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 1 Study of LY2787106 in Cancer and Anemia
A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
A Phase 1 Study of LY2787106 in Cancer and Anemia
A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Phase 1 Study of LY2787106 in Cancer and Anemia
A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Monica, CA
A Phase 1 Study of LY2787106 in Cancer and Anemia
A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Phase 1 Study of LY2787106 in Cancer and Anemia
A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
A Phase 1 Study of LY2787106 in Cancer and Anemia
A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials